Dual MTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

被引：0
|
作者：
Garcia-Garcia, C. [1 ]
Ibrahim, Y. H. [1 ]
Serra, V. [1 ]
Calvo, M. T. [1 ]
Aura, C. [1 ]
Perez, J. [1 ]
Rommel, C. [2 ]
Tabernero, J. [1 ]
Baselga, J. [3 ]
Scaltriti, M. [3 ]
机构：
[1] Vall dHebron Inst Oncol, Barcelona, Spain
[2] Intellikine Inc, La Jolla, CA USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)71437-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
804
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [31] Dual HER2 blockade: preclinical and clinical data
    Patel, Tejal A.
    Dave, Bhuvanesh
    Rodriguez, Angel A.
    Chang, Jenny C.
    Perez, Edith A.
    Colon-Otero, Gerardo
    BREAST CANCER RESEARCH, 2014, 16 (04):
  • [32] Dual HER2 blockade: preclinical and clinical data
    Tejal A Patel
    Bhuvanesh Dave
    Angel A Rodriguez
    Jenny C Chang
    Edith A Perez
    Gerardo Colon-Otero
    Breast Cancer Research, 16
  • [33] HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
    Alison E. Smith
    Emanuela Ferraro
    Anton Safonov
    Cristina Bernado Morales
    Enrique J. Arenas Lahuerta
    Qing Li
    Amanda Kulick
    Dara Ross
    David B. Solit
    Elisa de Stanchina
    Jorge Reis-Filho
    Neal Rosen
    Joaquín Arribas
    Pedram Razavi
    Sarat Chandarlapaty
    Nature Communications, 12
  • [34] Dual HER2 Blockade Slows Metastatic Breast Cancer
    Bender, Eric
    CANCER DISCOVERY, 2012, 2 (01)
  • [35] Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
    Giugliano, Federica
    Carnevale Schianca, Ambra
    Corti, Chiara
    Ivanova, Mariia
    Bianco, Nadia
    Dellapasqua, Silvia
    Criscitiello, Carmen
    Fusco, Nicola
    Curigliano, Giuseppe
    Munzone, Elisabetta
    CANCERS, 2023, 15 (05)
  • [36] Deregulation of HER2 Downstream Signaling in Breast Cancer Cells by a Cocktail of Anti-HER2 scFvs
    Nejatollahi, Foroogh
    Ranjbar, Reza
    Younesi, Vahid
    Asgharpour, Mahdi
    ONCOLOGY RESEARCH, 2012, 20 (08) : 333 - 340
  • [37] mTORC1 Activity Contributes to the Mcl-1 Dependence of HER2 Amplified Breast Cancer Cells
    Campone, M.
    Noel, B.
    Gouraud, W.
    Jezequel, P.
    Barille-Nion, S.
    Juin, P.
    CANCER RESEARCH, 2009, 69 (24) : 644S - 644S
  • [38] The HER2 CISH pharmDx™ Kit in the assessment of breast cancer patients for anti-HER2 treatment
    Foged, Niels T.
    Brugmann, Anja
    Jorgensen, Jan T.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2013, 13 (03) : 233 - 242
  • [39] Anti-HER2 vaccines: The HER2 immunotargeting future?
    Ladjemi, M. Z.
    Jacot, W.
    Pelegrin, A.
    Navarro-Teulon, I.
    PATHOLOGIE BIOLOGIE, 2011, 59 (03): : 173 - 182
  • [40] Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells
    Nejatollahi, Foroogh
    Jaberipour, Mansooreh
    Asgharpour, Mahdi
    TUMOR BIOLOGY, 2014, 35 (08) : 7887 - 7895
12345